A drug screening toolkit based on the -1 ribosomal frameshifting of SARS-CoV-2.

-1 ribosomal frameshifting Biomedical engineering Drug screen Microbial biotechnology Molecular biology Peptides Protein engineering SARS-Cov-2 Virology

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 14 07 2020
revised: 17 08 2020
accepted: 24 08 2020
entrez: 2 9 2020
pubmed: 2 9 2020
medline: 2 9 2020
Statut: ppublish

Résumé

The -1 ribosomal frameshifting is vital for the translation of the open reading frame (ORF)1b in SARS-CoV-2. The products of ORF1b participate in viral replication. Therefore, changing the frameshift frequency reduces the survival of the virus. This study aimed to successfully develop a toolkit for screening antiviral drugs. Finally, the FDA-approved drug library was screened, revealing that ivacaftor and (-)-Huperzine A worked well in changing the -1 ribosomal frameshifting of SARS-CoV-2

Identifiants

pubmed: 32869005
doi: 10.1016/j.heliyon.2020.e04793
pii: S2405-8440(20)31636-4
pii: e04793
pmc: PMC7448739
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e04793

Informations de copyright

© 2020 Published by Elsevier Ltd.

Références

J Virol. 2020 Oct 14;94(21):
pubmed: 32817221
Infect Disord Drug Targets. 2009 Apr;9(2):223-45
pubmed: 19275708
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
J Biol Chem. 2020 Jul 31;295(31):10741-10748
pubmed: 32571880
Pharmacol Res. 2020 Sep;159:104960
pubmed: 32473310
Nucleic Acids Res. 2005 Jul 29;33(13):4265-75
pubmed: 16055920
Science. 2020 Jun 26;368(6498):1422-1424
pubmed: 32461212
Gene. 1991 Jul 22;103(2):171-7
pubmed: 1889744
Nucleic Acids Res. 2004 Feb 03;32(2):784-90
pubmed: 14762205
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Antiviral Res. 2011 Jul;91(1):1-10
pubmed: 21549154
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15075-15084
pubmed: 32532919
Virology. 2005 Feb 20;332(2):498-510
pubmed: 15680415
Cell. 2019 Jan 24;176(3):625-635.e14
pubmed: 30682371
Wiley Interdiscip Rev RNA. 2012 Sep-Oct;3(5):661-73
pubmed: 22715123
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11133-8
pubmed: 12149516
J Am Chem Soc. 2011 Jul 6;133(26):10094-100
pubmed: 21591761
J Virol. 2010 May;84(9):4330-40
pubmed: 20164235

Auteurs

Yanqiong Chen (Y)

Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Huan Tao (H)

Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China.

Silan Shen (S)

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Zhiyong Miao (Z)

Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Lili Li (L)

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Yongqian Jia (Y)

Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China.

Hu Zhang (H)

Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Xiufeng Bai (X)

Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Xinyuan Fu (X)

Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.

Classifications MeSH